Shares of Mankind Pharma Ltd. surged 10% on Thursday, the highest single-day jump since its listing, after its first-quarter profit beat analysts' estimates.
The drugmaker's profit rose 66% year-on-year to Rs 487 crore in the April-June quarter, according to an exchange filing on Wednesday. That compares with the Rs 398 crore consensus estimate of analysts tracked by Bloomberg. Sequentially, the profit jumped 71%.
Mankind Pharma Q1 FY24 Highlights (Consolidated, YoY)
Revenue rose 18% to Rs 2,579 crore. (Bloomberg estimate: Rs 2,446 crore)
Ebitda was up 44% at Rs 655 crore. (Bloomberg estimate: Rs 560 crore)
Margin was 25.4% versus 20.9%. (Bloomberg estimate: 22.9%)
Shares of Mankind Pharma surged 8.75% to 1,892.05 apiece as of 10:43 a.m., compared to a 0.24% decline in the benchmark NSE Nifty 50. The stock jumped as much as 10% to Rs 1,913.75 apiece, the highest single-day jump since its listing on May 9.
The stock has risen 33% since listing. It hit a fresh record on July 24 at Rs 1,949 apiece and a record low of Rs 1,242 per share on May 22. The total traded volume stood at 8.5 times its 30-day average. The relative strength index at 60.9.
Ten of the 12 analysts tracking Mankind Pharma maintain a 'buy' rating on the stock, while two recommend a 'hold', according to Bloomberg data. The average of 12-month analyst price targets implies a potential downside of 16.4%.
RECOMMENDED FOR YOU
Sudeep Pharma IPO GMP In Focus As Subscription Enters Its Final Day
Emcure Pharma Shares Slip As Bain Capital Plans Rs 492.7 Crore Stake Sale
RVNL Q2 Results: Profit Declines For Second Straight Quarter Despite Revenue Jump
Jefferies Keeps Mankind Pharma Among Top Picks Despite Q2 Setback — Check Revised Target Price
POPULAR